146 related articles for article (PubMed ID: 8013984)
1. Therapeutic thrombocytapheresis: a review of 132 patients.
Adami R
Int J Artif Organs; 1993 Dec; 16 Suppl 5():183-4. PubMed ID: 8013984
[TBL] [Abstract][Full Text] [Related]
2. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.
Boddu P; Falchi L; Hosing C; Newberry K; Bose P; Verstovsek S
Leuk Res; 2017 Jul; 58():14-22. PubMed ID: 28380402
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
Murphy S
Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
[TBL] [Abstract][Full Text] [Related]
4. Managing uncontrolled postsplenectomy reactive thrombocytosis in idiopathic thrombocytopenic purpura: role of thrombocytapheresis.
Das SS; Bhattacharya S; Sen S
Transfus Apher Sci; 2013 Oct; 49(2):171-3. PubMed ID: 23871583
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic plateletpheresis in a case of symptomatic thrombocytosis in chronic myeloid leukemia.
Thakral B; Saluja K; Malhotra P; Sharma RR; Marwaha N; Varma S
Ther Apher Dial; 2004 Dec; 8(6):497-9. PubMed ID: 15663550
[TBL] [Abstract][Full Text] [Related]
6. [Chronic myeloproliferative diseases. Current therapeutic standards and new developments].
Krause SW; Mackensen A
Internist (Berl); 2008 Dec; 49(12):1452-7. PubMed ID: 18985309
[TBL] [Abstract][Full Text] [Related]
7. Safety and feasibility of therapeutic platelet depletion with Spectra Optia in a pregnant woman.
Małachowski R; Grzybowska-Izydorczyk O; Besson N; Szmigielska-Kapłon A; Nowicki M; Wierzbowska A
Transfus Apher Sci; 2017 Aug; 56(4):563-565. PubMed ID: 28803005
[TBL] [Abstract][Full Text] [Related]
8. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic thrombocytapheresis for extreme thrombocytosis after chemotherapy in essential thrombocytosis.
Almeida-Dias R; Garrote M; Cid J; Mustieles MJ; Alba C; Lozano M
J Clin Apher; 2019 Aug; 34(4):503-506. PubMed ID: 30624802
[TBL] [Abstract][Full Text] [Related]
10. The risk of thrombosis in essential thrombocythemia and polycythemia vera.
Pearson TC
Semin Oncol; 2002 Jun; 29(3 Suppl 10):16-21. PubMed ID: 12096353
[TBL] [Abstract][Full Text] [Related]
11. The effect of thrombocytapheresis on hemogram and biochemistry parameters in patients with essential thrombocytemia.
Kaya A; Kuku İ; Erkurt MA; Kaya E; Berber İ; Biçim S; Hidayet E; Cırık S; Arslan S; Yagin FH; Sarıcı A
Transfus Clin Biol; 2023 Nov; 30(4):421-425. PubMed ID: 37558046
[TBL] [Abstract][Full Text] [Related]
12. [Chronic myeloproliferative syndromes].
de Ozalla CB; García Suárez J
Rev Clin Esp; 1999 Apr; 199 Suppl 1():28-36. PubMed ID: 10422448
[No Abstract] [Full Text] [Related]
13. Pediatric Chronic Myeloid Leukemia Presenting With Extreme Thrombocytosis Simulating Essential Thrombocythemia.
Boklan JL; Walsh AM; de la Maza MC; Su LL; Nizzi FA; Schafernak KT
J Pediatr Hematol Oncol; 2018 Aug; 40(6):456-457. PubMed ID: 29668550
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
15. Bleeding and thrombosis in the myeloproliferative disorders.
Schafer AI
Blood; 1984 Jul; 64(1):1-12. PubMed ID: 6375757
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic thrombocytapheresis in patients with myeloproliferative diseases with the cell separators Fresenius AS 104 and Cobe Spectra: biocompatibility and safety].
Ullrich H; Kadar J; Waxenberger Y; Hohe R; Saueressig C; Heyder M; Wiebecke D
Beitr Infusionsther; 1992; 30():311-4. PubMed ID: 1284723
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic thrombocytapheresis in myeloproliferative neoplasms: A single-institution experience.
Nguyen TH; Bach KQ; Vu HQ; Nguyen NQ; Duong TD; Wheeler J
J Clin Apher; 2021 Feb; 36(1):101-108. PubMed ID: 33037852
[TBL] [Abstract][Full Text] [Related]
18. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
[TBL] [Abstract][Full Text] [Related]
19. Interferon alpha-2a to control thrombocytosis in chronic myelogenous leukemia and essential thrombocythemia.
Jootar S
Asian Pac J Allergy Immunol; 1989 Dec; 7(2):103-5. PubMed ID: 2624663
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Spivak JL
Semin Hematol; 2003 Jan; 40(1 Suppl 1):1-5. PubMed ID: 12682874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
